Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript

Pharming Group (PHAR) reported a robust Q2 2025, with total revenues increasing 26% year-over-year and achieving a $12.9 million operating profit, a significant turnaround from a loss in the prior year. This strong performance was driven by 28% growth in RUCONEST sales and accelerated patient uptake for Joenja. Consequently, the company upgraded its full-year 2025 revenue guidance, signaling positive momentum and improved financial health.

Analysis

Pharming Group reported a robust second quarter for 2025, demonstrating significant operational and commercial momentum. The company achieved total revenue growth of 26% year-over-year, alongside a notable turnaround in profitability, posting a $12.9 million operating profit compared to a loss in the prior-year period. This profit figure is particularly strong as it excludes $2 million in non-recurring expenses related to the Abliva acquisition. Growth was underpinned by strong performance from both key assets: the established product RUCONEST grew 28% year-on-year, while the newer drug, Joenja, showed accelerating patient uptake, with new patient additions in the first half of 2025 already exceeding the total for the entirety of 2024. This dual-engine growth and positive performance trajectory provided management the confidence to upgrade the full-year 2025 revenue guidance, signaling a strengthened outlook.

Key Decisions for Investors

• Given the strong top-line growth, a significant swing to operating profitability, and upgraded full-year guidance, the results serve as a strong validation of the company's commercial execution and may warrant a bullish reassessment of the stock's valuation.
• Investors should closely monitor the patient adoption rate for Joenja in the upcoming quarters, as its accelerating uptake is a critical driver for the company's growth narrative and supports the revised revenue forecast.
• The achievement of a $12.9 million operating profit marks a key financial inflection point; future reports should be evaluated for sustained profitability now that major non-recurring acquisition costs are accounted for.